Cite
MLA Citation
U. Kassner et al.. “Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies (Pcsk9-I) Treatment Of Cardiovascular High Risk Patients In Clinical Practice.” Atherosclerosis, vol. 287, 2019, pp. e212–. http://access.bl.uk/ark:/81055/vdc_100089678490.0x000048